Ketamine metabolite pilot study in a suicidal depression trial

Area of Science:

• Pharmacology and Psychiatry
• Neuroscience and Neurochemistry

Background:

• Ketamine offers rapid relief for depression and suicidal ideation but has limitations due to side effects and abuse potential.
• Investigating ketamine's metabolites may reveal mechanisms for developing safer therapeutic alternatives.

Purpose of the Study:

• To examine the relationship between ketamine and its metabolites, specifically hydroxynorketamine enantiomers, and clinical outcomes in patients with suicidal depression.
• To identify potential biomarkers for treatment response or lack thereof.

Main Methods:

• A post hoc analysis of a randomized, double-blind trial involving 53 adults with suicidal depression receiving ketamine or midazolam infusions.
• Measurement of ketamine and its metabolites, including (2S,6S)- and (2R,6R)-HNK, in plasma post-infusion.
• Correlation analysis (Spearman) between metabolite levels and changes in depression (HDRS-24) and suicidal ideation (SSI) scores.

Main Results:

• Elevated plasma levels of (2R,6R)-HNK were significantly associated with less improvement in depression and suicidal ideation at 24 hours post-infusion.
• Both (2R,6R)-HNK and (2S,6S)-HNK enantiomers, along with dehydronorketamine (DHNK), showed correlations with weekly clinical rating scores.
• Ketamine and norketamine levels were not significantly associated with changes in depression or suicidal ideation.

Conclusions:

• The metabolite (2R,6R)-HNK may play a role in modulating ketamine's antidepressant effects, with higher levels potentially indicating poorer response.
• These findings highlight the importance of studying ketamine metabolites to understand treatment mechanisms and develop safer, targeted therapies for depression.